Skip to content
Bored Studies
RecruitingPhase 1/Phase 2

ATR 1072 in Participants With PRKAG2 Syndrome

Atrium Therapeutics · NCT07738107

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–65 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 1, Phase 2
Target enrollment
37
US sites recruiting
1
Study start
September 14, 2026
Record last updated
September 18, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

ATR 1072 is an investigational medicine being studied in adults with PRKAG2 Syndrome. This study will evaluate the safety of ATR 1072 and how the body processes the drug. Researchers will also assess how ATR 1072 affects PRKAG2 activity and measures of heart disease.

Being studied: ATR 1072

Conditions: Cardiac Glycogenosis; Cardiomyopathy; Hypertrophic; Wolff-Parkinson-White Syndrome

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Adults 18 to 65 years of age.
  • Pathogenic, likely pathogenic, or variant of uncertain significance (VUS) in PRKAG2 confirmed by genetic testing.
  • Clinical manifestations consistent with PRKAG2 Syndrome.
  • Able and willing to comply with study procedures.
  • Able and willing to undergo endomyocardial biopsy procedures (Part A)

Exclusion Criteria

  • Pregnancy or breastfeeding.
  • Significant hepatic, renal, hematologic, or cardiovascular abnormalities that may increase study risk.
  • NYHA Class IV heart failure or left ventricular ejection fraction \<45%.
  • Recent clinically significant cardiovascular events or procedures.
  • Prior treatment with prohibited investigational therapies or oligonucleotide therapies within protocol-defined washout periods.
  • Any condition that, in the investigator's

Recruiting US locations

  • St Luke's Mid American Heart Institute

    Kansas City, MO 64111

    Site contact: Michael Nassif, MD · 816-932-3458 · michael.nassif@bjc.org

Study contacts (from the official record)

  • Patient Recruitment Coordinator · 283-227-6543 · clinicaltrials@atrium-tx.com
All heart & blood pressure studies in Missouri →
ATR 1072 in Participants With PRKAG2 Syndrome (NCT07738107) | Bored Studies